ArticleTranslational vision science & technology2025
P2X4 Receptor Antagonist Ameliorates Ocular Pain in Rats After Lacrimal Gland Removal.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose: The purinergic receptor P2X4 is critical to transduction of ocular pain. The aim of this study was to investigate the therapeutic potential of the P2X4 receptor antagonist BAY-776 in alleviating chronic ocular pain. Methods: Chronic ocular pain was induced in male rats (8-9 weeks old; n = 12 per group) via double lacrimal gland removal (DLGR). Rats were randomly assigned to receive vehicle control, 1.0 mg/mL BAY-776, or 2.5 mg/mL BAY-776 eyedrops after DLGR. Treatment efficacy was assessed with blink tests, wipe tests, and in vivo confocal microscopy (IVCM) at pre- and postsurgical baselines and 2 and 4 weeks of treatment. Corneal subbasal nerve plexus (SNP) density and inflammatory cells were quantified by IVCM image analysis and immunohistochemical staining. Efficacies of 2.5 mg/mL BAY-776 and 0.05% cyclosporine were also compared. Results: Compared with vehicle control, BAY-776 at both concentrations significantly reduced wipe and blink responses (P < 0.01). BAY-776 mitigated the increases in corneal SNP and inflammatory cell density after DLGR (P < 0.01). Notably, BAY-776 at 2.5 mg/mL reduced wipe test scores and inflammatory cell density at levels comparable to those of 0.05% cyclosporine (P < 0.001). Although cyclosporine did not significantly affect the blink test compared with vehicle, it reduced SNP density compared with BAY-776 (P < 0.05). Conclusions: The results indicate that BAY-776 effectively reduced chronic ocular pain in rats, showing efficacy similar to that of cyclosporine and underscoring its therapeutic potential for managing ocular pain. Translational Relevance: These results suggest that BAY-776 may be a promising option for managing chronic ocular pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.